RARE PHOTOS: Eisai | Vintage Vibes

Kidney Cancer Patients Gain New Two-Pill Option as FDA Approves Belzutifan Combo Without Proven Survival Benefit

FDA approves belzutifan with lenvatinib for advanced kidney cancer after immunotherapy. It delayed tumor growth, but the survival gain was not significant.

Medical Daily · Sep 25

Alzheimer's Treatment Can Now Begin at Home with an Injection Instead of Months of Infusions

The FDA approved an at-home subcutaneous starting dose of lecanemab. Launch is planned for late August, and monitoring requirements remain unchanged.

Medical Daily · Aug 13

Real World Study Tracked Lecanemab Outcomes Three Years After Approval Across Diverse United States Clinical Settings

Eisai's LEADER study reported that 83% of early Alzheimer's patients were stable or improved on Leqembi. Here is what a retrospective abstract can establish.

Medical Daily · Jul 28

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga · Oct 28, 2025

What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s disease accounts for around 60–80% of all cases.

The Conversation · Sep 29, 2025

The real reason two ‘miracle’ Alzheimer’s drugs were rejected for NHS use

ANALYSIS: Paul Atkinson and Sally Sheard say the decision reflects a cautious and evidence-based approach that protects patients and public funds

The Independent UK · Jun 25, 2025

Why Nice was right to say no – for now – to new Alzheimer’s drugs

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for routine NHS use in England. While disappointing for some families affected by dementia, this decision reflects a cautious and evidence-based approach that protects patients and public funds.

The Conversation · Jun 24, 2025

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

The Independent UK · Apr 16, 2025

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

The Independent UK · Nov 14, 2024

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times · Sep 20, 2024